Liacine Bouaoun
International Agency for Research on Cancer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Liacine Bouaoun.
Human Mutation | 2016
Liacine Bouaoun; Dmitriy Sonkin; Maude Ardin; Monica Hollstein; Graham Byrnes; Jiri Zavadil; Magali Olivier
TP53 gene mutations are one of the most frequent somatic events in cancer. The IARC TP53 Database (http://p53.iarc.fr) is a popular resource that compiles occurrence and phenotype data on TP53 germline and somatic variations linked to human cancer. The deluge of data coming from cancer genomic studies generates new data on TP53 variations and attracts a growing number of database users for the interpretation of TP53 variants. Here, we present the current contents and functionalities of the IARC TP53 Database and perform a systematic analysis of TP53 somatic mutation data extracted from this database and from genomic data repositories. This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000). However, the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations, such as the presence of a significant number of mutations occurring outside the DNA‐binding domain in specific cancer types. We also provide an update on TP53 inherited variants including the ones that should be considered as neutral frequent variations. We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database.
BMC Bioinformatics | 2016
Maude Ardin; Vincent Cahais; Xavier Castells; Liacine Bouaoun; Graham Byrnes; Zdenko Herceg; Jiri Zavadil; Magali Olivier
BackgroundThe nature of somatic mutations observed in human tumors at single gene or genome-wide levels can reveal information on past carcinogenic exposures and mutational processes contributing to tumor development. While large amounts of sequencing data are being generated, the associated analysis and interpretation of mutation patterns that may reveal clues about the natural history of cancer present complex and challenging tasks that require advanced bioinformatics skills. To make such analyses accessible to a wider community of researchers with no programming expertise, we have developed within the web-based user-friendly platform Galaxy a first-of-its-kind package called MutSpec.ResultsMutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources. MutSpec offers an accessible framework for building reproducible analysis pipelines, integrating existing methods and scripts developed in-house with publicly available R packages. MutSpec may be used to analyse data from whole-exome, whole-genome or targeted sequencing experiments performed on human or mouse genomes. Results are provided in various formats including rich graphical outputs. An example is presented to illustrate the package functionalities, the straightforward workflow analysis and the richness of the statistics and publication-grade graphics produced by the tool.ConclusionsMutSpec offers an easy-to-use graphical interface embedded in the popular Galaxy platform that can be used by researchers with limited programming or bioinformatics expertise to analyse mutation signatures present in cancer genomes. MutSpec can thus effectively assist in the discovery of complex mutational processes resulting from exogenous and endogenous carcinogenic insults.
Genome Medicine | 2017
Davide Degli Esposti; Athena Sklias; Sheila C.S. Lima; Stéphanie Beghelli-de la Forest Divonne; Vincent Cahais; Nora Fernandez-Jimenez; Marie-Pierre Cros; Szilvia Ecsedi; Cyrille Cuenin; Liacine Bouaoun; Graham Byrnes; Rosita Accardi; Anne Sudaka; Valérie Giordanengo; Hector Hernandez-Vargas; Luis Felipe Ribeiro Pinto; Ellen Van Obberghen-Schilling; Zdenko Herceg
BackgroundHead and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of cancers for which human papilloma virus (HPV) infection is an emerging risk factor. Previous studies showed promoter hypermethylation in HPV(+) oropharyngeal cancers, but only few consistent target genes have been so far described, and the evidence of a functional impact on gene expression is still limited.MethodsWe performed global and stratified pooled analyses of epigenome-wide data in HNSCCs based on the Illumina HumanMethylation450 bead-array data in order to identify tissue-specific components and common viral epigenetic targets in HPV-associated tumours.ResultsWe identified novel differentially methylated CpGs and regions associated with viral infection that are independent of the anatomic site. In particular, most hypomethylated regions were characterized by a marked loss of CpG island boundaries, which showed significant correlations with expression of neighbouring genes. Moreover, a subset of only five CpGs in a few hypomethylated regions predicted HPV status with a high level of specificity in different cohorts. Finally, this signature was a better predictor of survival compared with HPV status determined by viral gene expression by RNA sequencing in The Cancer Genome Atlas cohort.ConclusionsWe identified a novel epigenetic signature of HPV infection in HNSCCs which is independent of the anatomic site, is functionally correlated with gene expression and may be leveraged for improved stratification of prognosis in HNSCCs.
International Journal of Cancer | 2017
Estelle Chanudet; Magdalena B. Wozniak; Liacine Bouaoun; Graham Byrnes; Anush Mukeriya; David Zaridze; Paul Brennan; David C. Muller; Ghislaine Scelo
Circulating miRNAs have shown great promises as noninvasive diagnostic and predictive biomarkers in several solid tumors. While the miRNA profiles of renal tumors have been extensively explored, knowledge of their circulating counterparts is limited. Our study aimed to provide a large‐scale genome‐wide profiling of plasma circulating miRNA in clear‐cell renal cell carcinoma (ccRCC). Plasma samples from 94 ccRCC cases and 100 controls were screened for 754 circulating micro‐RNAs (miRNA) by TaqMan arrays. Analyses including known risk factors for renal cancer—namely, age, sex, hypertension, obesity, diabetes, tobacco smoking and alcohol consumption—highlighted that circulating miRNA profiles were tightly correlated with the stage of the disease. Advanced tumors, characterized as stage III and IV, were associated with specific miRNA signatures that significantly differ from both controls and earlier stage ccRCC cases. Molecular pathway enrichment analyses of their gene targets showed high similarities with alterations observed in renal tumors. Plasma circulating levels of miR‐150 were significantly associated with RCC‐specific survival and could marginally improve the predictive accuracy of clinical parameters in our series, including age at diagnosis, sex and conventional staging. In summary, our results suggest that circulating miRNAs may provide insights into renal cell carcinoma progression.
bioRxiv | 2018
Maria Zhivagui; Maude Ardin; Alvin Wei Tian Ng; Mona I. Churchwell; Manuraj Pandey; Stephanie Villar; Vincent Cahais; Alexis Robitaille; Liacine Bouaoun; Adriana Heguy; Kathryn Z. Guyton; Martha R. Stampfer; James D. McKay; Monica Hollstein; Magali Olivier; Steven G. Rozen; Frederick A. Beland; Michael Korenjak; Jiri Zavadil
Acrylamide, a probable human carcinogen, is ubiquitously present in the human environment, with sources including heated starchy foods, coffee and cigarette smoke. Humans are also exposed to acrylamide occupationally. Acrylamide is genotoxic, inducing gene mutations and chromosomal aberrations in various experimental settings. Covalent haemoglobin adducts were reported in acrylamide-exposed humans and DNA adducts in experimental systems. The carcinogenicity of acrylamide has been attributed to the effects of glycidamide, its reactive and mutagenic metabolite capable of inducing rodent tumors at various anatomical sites. In order to characterize the pre-mutagenic DNA lesions and global mutation spectra induced by acrylamide and glycidamide, we combined DNA-adduct and whole-exome sequencing analyses in an established exposure-clonal immortalization system based on mouse embryonic fibroblasts. Sequencing and computational analysis revealed a unique mutational signature of glycidamide, characterized by predominant T:A>A:T transversions, followed by T:A>C:G and C:G>A:T mutations exhibiting specific trinucleotide contexts and significant transcription strand bias. Computational interrogation of human cancer genome sequencing data indicated that a combination of the glycidamide signature and an experimental benzo[a]pyrene signature are nearly equivalent to the COSMIC tobacco-smoking related signature 4 in lung adenocarcinomas and squamous cell carcinomas. We found a more variable relationship between the glycidamide‐ and benzo[a]pyrene-signatures and COSMIC signature 4 in liver cancer, indicating more complex exposures in the liver. Our study demonstrates that the controlled experimental characterization of specific genetic damage associated with glycidamide exposure facilitates identifying corresponding patterns in cancer genome data, thereby underscoring how mutation signature laboratory experimentation contributes to the elucidation of cancer causation. A 40-word summary Innovative experimental approaches identify a novel mutational signature of glycidamide, a metabolite of the probable human carcinogen acrylamide. The results may elucidate the cancer risks associated with exposure to acrylamide, commonly found in tobacco smoke, thermally processed foods and beverages.
Cancer Epidemiology | 2018
Daniel Middleton; Liacine Bouaoun; Rachel Hanisch; Freddie Bray; Charles Dzamalala; Steady Chasimpha; Diana Menya; Charles Gombe Mbalawa; Guy N’Da; Mathewos A. Woldegeorgis; Ramou Njie; Moussa Koulibaly; Nathan Buziba; Josefo Ferro; Hassan Nouhou; Femi Ogunbiyi; Henry Wabinga; Eric Chokunonga; Margaret Borok; Anne Korir; Amos O. Mwasamwaja; Blandina T. Mmbaga; Joachim Schüz; Valerie McCormack
Highlights • We conducted a review and meta-analysis of esophageal cancer sex ratios in mainland Africa using data from 197 populations in 36 countries.• We observed a consistent male excess in incidence rates overall and in the high-risk Eastern and Southern African regions.• A male excess was evident in 30–39 year olds in high-risk Eastern and Southern African regions.• Our findings suggest that a substantial fraction of the African EC burden could be avoided by targeting gender-specific exposures.
bioRxiv | 2018
Magali Olivier; Liacine Bouaoun; Stephanie Villar; Alexis Robitaille; Vincent Cahais; Adriana Heguy; Graham Byrnes; Florence Le Calvez-Kelm; Gabriela Torres-Mejía; Isabel Alvarado-Cabrero; Fazlollah Shahram Imani-Razavi; Gloria Inés Sánchez; Roberto Jaramillo; Carolina Porras; Ana Cecilia Rodriguez; Maria Luisa Garmendia; Jose Luis Soto; Isabelle Romieu; Peggy L. Porter; Jamie Guenthoer; Sabina Rinaldi
Background In Latin America (LA), there is a high incidence rate of breast cancer (BC) in premenopausal women, and the genomic features of these BC remain unknown. Here, we aim to characterize the molecular features of BC in young LA women within the framework of the PRECAMA study, a multicenter population-based case-control study on breast cancer in premenopausal women. Methods Pathological tumor tissues were collected from incident cases from four LA countries. Immunohistochemistry (IHC) was performed centrally for ER, PR, HER2, Ki67, EGFR, CK5/6 and p53 protein markers. Targeted deep sequencing was done on genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour tissues and their paired blood samples to screen for somatic mutations in eight genes frequently mutated in BC. A subset of samples was analyzed by exome sequencing to identify somatic mutational signatures. Results The majority of cases were positive for ER or PR (168/233; 72%) and there were 21% triple negative (TN) cases, mainly of basal type. Most tumors were positive for Ki67 (189/233; 81%). In 126 sequenced cases, TP53 and PIK3CA were the most frequently mutated genes (32.5% and 21.4%, respectively), followed by AKT1 (9.5%). TP53 mutations were more frequent in HER2-enriched and TN IHC subtypes, while PIK3CA/AKT1 mutations were more frequent in ER positive tumors, as expected. Interestingly, a higher proportion of G:C>T:A mutations was observed in TP53 gene in PRECAMA cases compared to TCGA and METABRIC breast cancer series (27% vs 14%). Exome-wide mutational patterns in 10 TN cases revealed alterations in signaling transduction pathways and major contributions of mutational signatures caused by altered DNA repair pathways. Conclusions This pilot results on PRECAMA tumors gives a preview of the molecular features of premenopausal BC in LA. Although, the overall mutation burden was as expected from data in other populations, mutational patterns observed in TP53 and exome-wide suggested possible differences in mutagenic processes giving rise to these tumors compared to other populations. Further omics analyses of a larger number of cases in the near future will allow investigating relationships between these molecular features and risk factors.
Poster Presentation: Cancer Genomics, Epigenetics and Genomic Instability | 2018
Magali Olivier; Liacine Bouaoun; G Torres-Mejia; Ml Garmendia; Gloria Inés Sánchez; C Porras; Isabelle Romieu; Peggy L. Porter; Sabina Rinaldi
Introduction In Latin America (LA), there is a high incidence rate of breast cancer (BC) in premenopausal women, and the genomic features of these BC remain unknown. Here, we have characterised the molecular features of BC in young LA women within the framework of the PRECAMA study, a multicenter population-based case-control study on breast cancer in premenopausal women. Material and methods Pathological tumour tissues were collected from incident cases from four LA countries. Immunohistochemistry (IHC) was performed centrally for ER, PR, HER2, Ki67, EGFR, CK5/6 and p53 protein markers. Targeted deep sequencing was done on genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour tissues and their paired blood samples to screen for somatic mutations in eight genes frequently mutated in BC. A subset of samples was analysed by exome sequencing to identify somatic mutational signatures. Results and discussions The majority of cases were positive for ER or PR (168/233; 72%) and 21% of cases were triple negative (TN), mainly of basal type. Most tumours were positive for Ki67 (189/233; 81%). In 126 sequenced cases, TP53 and PIK3CA were the most frequently mutated genes (32.5% and 21.4%, respectively), followed by AKT1 (9.5%). TP53 mutations were more frequent in HER2-enriched and TN IHC subtypes, while PIK3CA/AKT1 mutations were more frequent in ER-positive tumours, as expected. Interestingly, a higher proportion of G:C>T:A mutation type was observed in TP53 gene in PRECAMA cases compared to TCGA and METABRIC breast cancer series (27% vs 14%). Exome-wide mutational patterns in 10 TN cases revealed alterations in signalling transduction pathways and major contributions of mutational signatures caused by altered DNA repair pathways. Conclusion This pilot study on PRECAMA tumours gives a preview of the molecular features of premenopausal BC in LA. Although the overall mutation burden was as expected from data in other populations, mutational patterns observed in TP53 and exome-wide suggested possible differences in mutagenic processes giving rise to these tumours compared to other populations. Further omics analyses of a larger number of cases in the near future will allow investigating relationships between these molecular features and risk factors.
European Journal of Cancer | 2017
Srikant Ambatipudi; Steve Horvath; Flavie Perrier; Cyrille Cuenin; Hector Hernandez-Vargas; Florence Le Calvez-Kelm; Geoffroy Durand; Graham Byrnes; Pietro Ferrari; Liacine Bouaoun; Athena Sklias; Véronique Chajès; Kim Overvad; Gianluca Severi; Laura Baglietto; Françoise Clavel-Chapelon; Rudolf Kaaks; Myrto Barrdahl; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Androniki Naska; Giovanna Masala; Claudia Agnoli; Silvia Polidoro; Rosario Tumino; Salvatore Panico; Martijn E.T. Dollé; Petra H. Peeters; N. Charlotte Onland-Moret
Cancer Research | 2018
Manuraj Pandey; Maria Zhivagui; Mona I. Churchwell; Alvin Wei Tian Ng; Liacine Bouaoun; Vincent Cahais; Martha R. Stampfer; Magali Olivier; Zdenko Herceg; Ewy Mathe; Steven G. Rozen; Frederick A. Beland; Michael Korenjak; Jiri Zavadil